Peregrine Asset Advisers’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $333K | Sell |
632
-50
| -7% | -$28K | 0.07% | 166 |
|
|
2026
Q1 | $383K | Hold |
682
| – | – | 0.1% | 138 |
|
|
2025
Q4 | $461K | Hold |
682
| – | – | 0.13% | 110 |
|
|
2025
Q3 | $436K | Sell |
682
-30
| -4% | -$18.2K | 0.13% | 114 |
|
|
2025
Q2 | $382K | Hold |
712
| – | – | 0.12% | 116 |
|
|
2025
Q1 | $299K | Hold |
712
| – | – | 0.11% | 129 |
|
|
2024
Q4 | $294K | Sell |
712
-74
| -9% | -$32.5K | 0.11% | 130 |
|
|
2024
Q3 | $397K | Sell |
786
-30
| -4% | -$14.6K | 0.14% | 115 |
|
|
2024
Q2 | $398K | Hold |
816
| – | – | 0.16% | 106 |
|
|
2024
Q1 | $441K | Sell |
816
-2
| -0.2% | -$1.09K | 0.18% | 99 |
|
|
2023
Q4 | $454K | Hold |
818
| – | – | 0.22% | 89 |
|
|
2023
Q3 | $358K | Buy |
818
+165
| +25% | +$82.3K | 0.19% | 100 |
|
|
2023
Q2 | $328K | Hold |
653
| – | – | 0.25% | 55 |
|
|
2023
Q1 | $327K | Hold |
653
| – | – | 0.32% | 48 |
|
|
2022
Q4 | $266K | Hold |
653
| – | – | 0.28% | 44 |
|
|
2022
Q3 | $213K | Hold |
653
| – | – | 0.25% | 54 |
|
|
2022
Q2 | $229K | Sell |
653
-700
| -52% | -$285K | 0.17% | 74 |
|
|
2022
Q1 | $740K | Hold |
1,353
| – | – | 0.38% | 54 |
|
|
2021
Q4 | $891K | Hold |
1,353
| – | – | 0.36% | 60 |
|
|
2021
Q3 | $841K | Hold |
1,353
| – | – | 0.43% | 52 |
|
|
2021
Q2 | $854K | Hold |
1,353
| – | – | 0.39% | 53 |
|
|
2021
Q1 | $662K | Hold |
1,353
| – | – | 0.34% | 59 |
|
|
2020
Q4 | $676K | Hold |
1,353
| – | – | 0.32% | 65 |
|
|
2020
Q3 | $532K | Buy |
1,353
+725
| +115% | +$268K | 0.29% | 62 |
|
|
2020
Q2 | $207K | Hold |
628
| – | – | 0.12% | 91 |
|
|
2020
Q1 | $152K | Buy |
+628
| New | +$164K | 0.11% | 94 |
|
|
2015
Q2 | – | Sell |
-56,542
| Closed | -$4.37M | – | 123 |
|
|
2015
Q1 | $4.37M | Sell |
56,542
-27,214
| -32% | -$2.12M | 2.86% | 7 |
|
|
2014
Q4 | $6.21M | Buy |
83,756
+60,690
| +263% | +$4.26M | 4.37% | 2 |
|
|
2014
Q3 | $1.36M | Buy |
+23,066
| New | +$1.46M | 1.12% | 33 |
|
|
2014
Q2 | – | Sell |
-93,390
| Closed | -$5.67M | – | 123 |
|
|
2014
Q1 | $5.67M | Buy |
93,390
+43,840
| +88% | +$2.61M | 4.38% | 3 |
|
|
2013
Q4 | $2.63M | Buy |
+49,550
| New | +$2.61M | 2.3% | 12 |
|
Other funds holding IDXX
Peregrine Asset Advisers's IDXX Position: Q2 2026 in Review
Peregrine Asset Advisers reduced its Idexx Laboratories (IDXX) stake by 7.3% in Q2 2026, selling an estimated $28K and leaving 632 shares worth $333K. The position accounts for 0.07% of the portfolio, ranked #166.
Peregrine Asset Advisers first reported a position in IDXX in Q4 2013 and has held it in 31 quarters since. The position peaked at $6.21M in Q4 2014. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Peregrine Asset Advisers held 632 shares of Idexx Laboratories worth $333K as of Q2 2026.
- Peregrine Asset Advisers sold 50 Idexx Laboratories shares in Q2 2026, an estimated $28K.
- Idexx Laboratories made up 0.07% of Peregrine Asset Advisers's portfolio in Q2 2026, its #166 holding.
- Peregrine Asset Advisers first reported a position in Idexx Laboratories in Q4 2013 and has held it in 31 quarters since.
- Peregrine Asset Advisers's Idexx Laboratories position peaked at $6.21M in Q4 2014.
- 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.